Advertisement

Topics

Neptune to Hold Conference Call to Discuss the Transaction with Aker BioMarine

20:00 EDT 7 Aug 2017 | Marketwired

LAVAL, QUEBEC -- (Marketwired) -- 08/08/17 -- Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ: NEPT)(TSX: NEPT), announces that it will be holding a conference call today on August 8, 2017 at 9:00 AM (EST) to discuss the transaction with Aker BioMarine.

A replay of the call will be available for replay two hours after the call's completion, until September 8, 2017. The telephone numbers to access the replay of the call are 1 (416) 621-4642 or 1 (800) 585-8367 (toll-free), Conference ID 67354926. The archive of the webcast, along with its accompanying presentation, will also be made available immediately in the Investors section of Neptune's website under Investor Events and Presentations.

About Neptune Technologies & Bioressources Inc.

Neptune is a wellness products company, with more than 50 years of combined experience in the industry. The Company develops turnkey solutions available in various unique delivery forms, offers specialty ingredients such as MaxSimil®, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and a variety of other marine and seed oils. Neptune also sells premium krill oil directly to consumers through web sales at www.oceano3.com. Leveraging our scientific, technological and innovative expertise Neptune is working to develop unique extractions in high potential growth segments such as in the medical cannabis field.

Neptune is also pursuing opportunities in the prescription drug markets, through its 34% owned subsidiary Acasti Pharma Inc. ("Acasti"). Acasti focuses on the research, development and commercialization of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia.

The Company's head office is located in Laval, Quebec.

Contacts: Neptune Wellness Solutions Mario Paradis VP & CFO, Neptune 450-687-2262 x236 Investor Relations Contact (Canada) Pierre Boucher MaisonBrison 1.514.731.0000 Investor Relations Contact (U.S.) James Carbonara Hayden IR 1.646.755.4712 NEXT ARTICLE

More From BioPortfolio on "Neptune to Hold Conference Call to Discuss the Transaction with Aker BioMarine "

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Prescription Drugs
A prescription drug (also prescription medication or prescription medicine) is a licensed medicine that is regulated by legislation to require a medical prescription before it can be obtained. The term is used to distinguish it from over-the-counter drug...

Hyperlipidemia - high cholesterol (hypercholesterolaemia)
Hyperlipidemia involves abnormally elevated levels of any or all lipids and/or lipoproteins in the blood. Lipids are transported in a protein capsule, the size of that capsule, or lipoprotein, determines its density. The lipoprotein density and type...